OR WAIT null SECS
The hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai discussed which patient groups he believes require more attention.
In an interview with CancerNetwork®, Guido Lancman, MD, hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai, highlighted which multiple myeloma patient populations he believes require further research.
So, there are still several populations that are not receiving the same benefit from all of these new therapies. And that's patients with high-risk cytogenetics, elderly patients, frail patients, patients with renal failure, and then of course, patients who have exhausted all therapies there’s always a need to develop new therapies for those patients.